Ryan D. Maynard
Chief Financial Officer, RIGEL PHARMACEUTICALS INC.
Companies
- Foghorn Therapeutics Inc.Chief financial officer Feb 24, 2026 to now1
- Iovance BiotherapeuticsBoard member Feb 17, 2015 to now2
- Tvardi Therapeutics, Inc.Chief financial officer Sep 14, 2022 to Feb 12, 20243
- RIGEL PHARMACEUTICALS INCChief financial officer Jun 2, 2006 to Nov 7, 20174
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Iovance Biotherapeutics IOVA7,500 shares5$110.4K at $14.72Nov 12, 2024
- Tvardi Therapeutics, Inc. TVRD13,500 shares6$14.4K at $1.06Feb 1, 2024
As of each latest filing. The line shows shares held over time.
Recent filings
- Nov 12, 2024Sold 50,000 shares at $10.06 of Iovance Biotherapeutics5
- Nov 12, 2024Exercised options 50,000 shares at $7.45 of Iovance Biotherapeutics5
- Feb 1, 2024Granted 13,500 shares of Tvardi Therapeutics, Inc.6
- Feb 8, 2023Sold 5,488 shares at $0.53 of Tvardi Therapeutics, Inc.7
- May 31, 2022Bought 7,500 shares at $6.75 of Iovance Biotherapeutics8
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7SEC EDGARForm 4 filed Feb 12, 2024
- 8SEC EDGARForm 4 filed Jun 2, 2022